Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing, and commercialization of pharmaceutical products with a primary focus on neurodegenerative diseases, oncology and supportive care, and hospital products. Its products portfolio includes Redesca, a low molecular weight heparin (LMWH) biosimilar to treat and prevent deep vein thrombosis and pulmonary embolism; Hesperco, a capsule that supports the immune system; Onstryv, an oral medication for Parkinson's disease; M-Eslon, a narcotic analgesic for pain management; and Ametop Gel, a tetracaine hydrochloride gel for the percutaneous anesthetic to produce anesthesia of the skin prior to venepuncture or venous cannulation. The company also provides Ethacrynate Sodium, a loop diuretic used to treat high blood pressure and the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure; Synacthen Depot, a synthetic adrenocorticotropic hormone to treat multiple sclerosis and nephrotic syndrome; Ondansetron for the prevention of nausea and vomiting caused by cancer chemotherapy; Benztropine, an anticholinergic agent used for the treatment of Parkinson's disease; and Yondelis, a novel marine-derived antitumor agent for the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy. In addition, its product pipeline includes Piperacillin/tazobactam, an injectable antibiotic, as well as various hospital products for anti-fungal, antibiotic, pain management, and other indications. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.